betamethasone acetate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
349 987-24-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betamethasone acetate
A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
  • Molecular weight: 434.50
  • Formula: C24H31FO6
  • CLOGP: 2.32
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 100.90
  • ALOGS: -4.42
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.06 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.075 Moderate 0.65
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.945 Moderate 0.65
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 46.881 10^-6 cm/s Moderate 0.65
dh-clint Dog hepatocyte intrinsic clearance 15.066 uL/min/10^6 cells Moderate 0.65
dppb Dog plasma protein binding (% unbound) 36.310 % Moderate 0.65
fcs-ppb Fetal calf serum protein binding (% unbound) 44.500 % Moderate 0.65
herg hERG pIC50 4.437 pIC50 Moderate 0.65
hh-clint Human hepatocyte intrinsic clearance 12.106 uL/min/10^6 cells Moderate 0.65
hlm-clint Human liver microsomal intrinsic clearance 30.479 uL/min/mg protein Moderate 0.65
hppb Human plasma protein binding (% unbound) 25.130 % Moderate 0.65
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 11.350 Moderate 0.79
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 5.458 Moderate 0.65
mh-clint Mouse hepatocyte intrinsic clearance 52.966 Moderate 0.65
mppb Mouse plasma protein binding (% unbound) 30.580 Moderate 0.65
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 11.588 Moderate 0.65
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.79
pppb Pig plasma protein binding (% unbound) 36.420 % Moderate 0.65
rat-kpuu-brain Rat brain Kpuu 0.080 % Moderate 0.79
rh-clint Rat hepatocyte intrinsic clearance 76.560 uL/min/10^6 cells Moderate 0.65
rh-fuinc Rat hepatocyte fraction unbound in incubation 76.180 % Moderate 0.65
rppb Rat plasma protein binding (% unbound) 23.320 % Moderate 0.65
solubility-dd Solubility at pH 7.4 in DMSO 368.978 uM Moderate 0.65

Approvals:

DateAgencyCompanyOrphan
March 3, 1965 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
CHEBI has role CHEBI:35472 anti-inflammatory drug
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35705 immunosuppressive agent
CHEBI has role CHEBI:35845 gout suppressant
CHEBI has role CHEBI:39456 antiglaucoma drug
CHEBI has role CHEBI:49201 anti-ulcer drug
CHEBI has role CHEBI:50177 dermatologic drug
CHEBI has role CHEBI:50748 antipsoriatic
CHEBI has role CHEBI:51177 antitussive
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:77715 nasal decongestant
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:67079 anti-inflammatory agent
CHEBI has role CHEBI:75835 anti-anaemic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cerebral edema indication 2032001
Berylliosis indication 8247009 DOID:10322
Psoriasis indication 9014002 DOID:8893
Ankylosing spondylitis indication 9631008 DOID:7147
Rheumatic heart disease indication 23685000
Atopic dermatitis indication 24079001 DOID:3310
Inflammatory bowel disease indication 24526004 DOID:0050589
Multiple sclerosis indication 24700007 DOID:2377
Severe adrenal insufficiency indication 24867002
Sarcoidosis indication 31541009 DOID:11335
Idiopathic thrombocytopenic purpura indication 32273002 DOID:8924
Psoriasis with arthropathy indication 33339001
Crohn's disease indication 34000006
Tendinitis indication 34840004 DOID:971
Erythema multiforme indication 36715001
Contact dermatitis indication 40275004 DOID:2773
Angioedema indication 41291007 DOID:1558
Humoral hypercalcemia of malignancy indication 47709007
Articular gout indication 48440001 DOID:13189
Edema of larynx indication 51599000
Nephrotic syndrome indication 52254009 DOID:1184
Systemic lupus erythematosus indication 55464009 DOID:9074
Allergic rhinitis indication 61582004
Löffler's syndrome indication 64936001 DOID:9503
Pemphigus indication 65172003 DOID:9182
Tenosynovitis indication 67801009 DOID:970
Rheumatoid arthritis indication 69896004 DOID:7148
Transfusion reaction due to serum protein reaction indication 72284000
Acquired thrombocytopenia indication 74576004 DOID:11126
Thyroiditis indication 82119001 DOID:7166
Bursitis indication 84017003 DOID:2965
Autoimmune disease indication 85828009
Infection by larvae of Trichinella spiralis indication 88264003
Acute lymphoid leukemia indication 91857003 DOID:9952
Dermatitis herpetiformis indication 111196000 DOID:8505
Hodgkin's disease indication 118599009
Non-Hodgkin's lymphoma indication 118601006
Mycosis fungoides indication 118618005
Aspiration pneumonitis indication 155597006
Asthma indication 195967001 DOID:2841
Transplanted organ rejection indication 213148006
Adrenogenital disorder indication 267395000 DOID:0050811
Eruption of skin indication 271807003 DOID:0050486
Disorder of eye indication 371405004 DOID:5614
Adrenal cortical hypofunction indication 386584007 DOID:10493
Erythroderma indication 399992009
Autoimmune hemolytic anemia indication 413603009 DOID:718
Synovitis indication 416209007 DOID:2703
Post traumatic osteoarthritis indication 699262001
Systemic Dermatomyositis indication
Transfusion Reaction Urticaria indication
Erythroblastic Anemia indication
Synovitis due to Osteoarthritis indication
Respiratory distress syndrome in the newborn off-label use 46775006
Congenital hypoplastic anemia off-label use 88854002 DOID:1339
Neonatal Bronchopulmonary Dysplasia off-label use
Infection by Strongyloides contraindication 1214006 DOID:10955
Mycosis contraindication 3218000 DOID:1564
Gastritis contraindication 4556007 DOID:4029
Inactive tuberculosis contraindication 11999007
Peptic ulcer contraindication 13200003 DOID:750
Hypercholesterolemia contraindication 13644009
Measles contraindication 14189004 DOID:8622
Cirrhosis of liver contraindication 19943007 DOID:5082
Arginase deficiency contraindication 23501004 DOID:9278
Immunosuppression contraindication 38013005
Hypertensive disorder contraindication 38341003 DOID:10763
Infectious disease contraindication 40733004
Hypothyroidism contraindication 40930008 DOID:1459
Hypokalemia contraindication 43339004
Chronic heart failure contraindication 48447003
Cerebral malaria contraindication 53622003 DOID:14069
Tuberculosis contraindication 56717001
Congenital hyperammonemia, type I contraindication 62522004
Osteoporosis contraindication 64859006 DOID:11476
Psychotic disorder contraindication 69322001
Diabetes mellitus contraindication 73211009 DOID:9351
Hypopituitarism contraindication 74728003 DOID:9406
Hyperglycemia contraindication 80394007 DOID:4195
Ornithine Carbamyltransferase Deficiency contraindication 80908008 DOID:9271
Open-angle glaucoma contraindication 84494001 DOID:1067
Muscle atrophy contraindication 88092000 DOID:767
Herpes simplex contraindication 88594005 DOID:8566
Bilateral cataracts contraindication 95722004
Seizure disorder contraindication 128613002
Disorder of muscle contraindication 129565002 DOID:423
Ophthalmic herpes simplex contraindication 186542001
Anastomosis of intestine contraindication 235407009
Edema contraindication 267038008
Pathological fracture contraindication 268029009
Diverticulitis of gastrointestinal tract contraindication 271366000
Cerebral trauma contraindication 275382005
Varicella-zoster virus infection contraindication 309465005
Osteopenia contraindication 312894000
Avascular necrosis of bone contraindication 397758007 DOID:10159
Citrullinemia contraindication 398680004 DOID:9273
Traumatic rupture of tendon contraindication 415749005
Exposure to varicella contraindication 444453009
Arginosuccinate Lyase Deficiency contraindication




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Pruritus associated with dermatoses Indication
Dogs Pruritus associated with dermatoses Indication
Horses Inflammatory joint conditions Indication

🐶 Veterinary products

ProductApplicantIngredients
Betavet Soluspan Suspension Intervet Inc. 2
Gentocin Durafilm Intervet Inc. 2
BetaVet American Regent Inc. 2
Osurnia Dechra, Ltd. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.06 acidic
pKa2 13.41 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
4018645 VUID
N0000146958 NUI
D01402 KEGG_DRUG
1514 RXNORM
C0005310 UMLSCUI
CHEMBL1200538 ChEMBL_ID
C580789 MESH_SUPPLEMENTAL_RECORD_UI
TI05AO53L7 UNII
443967 PUBCHEM_CID
DB00443 DRUGBANK_ID
10006 MMSL
4270 MMSL
4271 MMSL
72315 MMSL
d00628 MMSL
C0005308 UMLSCUI
9782 PUBCHEM_CID
1045 INN_ID
4018644 VANDF
4018645 VANDF
D001623 MESH_DESCRIPTOR_UI
002168 NDDF
002169 NDDF
116571008 SNOMEDCT_US
116572001 SNOMEDCT_US
29896003 SNOMEDCT_US
CHEBI:3077 CHEBI
TI05AO53L7 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0720 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0791 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 0517-0799 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betamethasone Sodium Phosphate and Betamethasone Acetate HUMAN PRESCRIPTION DRUG LABEL 2 76420-007 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR ANDA 21 sections
Betaloan SUIK HUMAN PRESCRIPTION DRUG LABEL 2 76420-240 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR unapproved drug other 21 sections
CELESTONE SOLUSPAN HUMAN PRESCRIPTION DRUG LABEL 2 78206-118 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA 22 sections
Betaloan SUIK HUMAN PRESCRIPTION DRUG LABEL 2 80425-0347 INJECTION, SUSPENSION 3 mg INTRA-ARTICULAR unapproved drug other 21 sections
CELESTONE SOLUSPAN HUMAN PRESCRIPTION DRUG LABEL 2 85766-070 INJECTION, SUSPENSION 3 mg INTRAMUSCULAR NDA 22 sections